Vor Biopharma (VOR) News Today $2.48 -0.20 (-7.30%) As of 11:32 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VOR Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Vor Biopharma Target of Unusually High Options Trading (NYSE:VOR)1 hour ago | marketbeat.comAnalysts Set Vor Biopharma Inc. (NYSE:VOR) Price Target at $5.63July 8 at 2:39 AM | americanbankingnews.comBoston’s biotech sector reels due to Trump health policy uncertaintyJuly 6 at 3:56 PM | ft.comVor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJuly 5 at 2:37 AM | marketbeat.comHC Wainwright Predicts Weaker Earnings for Vor BiopharmaJuly 4, 2025 | americanbankingnews.comVor Biopharma Q2 EPS Estimate Decreased by HC WainwrightJuly 2, 2025 | marketbeat.comHC Wainwright Upgrades Vor Biopharma (NYSE:VOR) to "Buy"July 2, 2025 | americanbankingnews.comVor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 1, 2025 | globenewswire.comHC Wainwright & Co. Upgrades Vor Biopharma (VOR)June 30, 2025 | msn.comVor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune MarketJune 30, 2025 | benzinga.comVor Biopharma (NYSE:VOR) Upgraded at HC WainwrightJune 30, 2025 | marketbeat.comVor Biopharma Inc. Stock Grades - Barron'sJune 27, 2025 | barrons.comVor Biopharma (NYSE:VOR) Stock Price Expected to Rise, Robert W. Baird Analyst SaysJune 27, 2025 | marketbeat.comVor Biopharma Insider Trading Activity | NASDAQ:VOR | BenzingaJune 26, 2025 | benzinga.comVor Biopharma Shares Skyrocket on Global Licensing Deal for Autoimmune TherapyJune 26, 2025 | msn.comVor Biopharma: Vor Bio Announces $175 Million Private PlacementJune 26, 2025 | finanznachrichten.deVor Biopharma: Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune AssetJune 26, 2025 | finanznachrichten.deVor Biopharma stock soars after licensing deal for autoimmune therapyJune 26, 2025 | investing.comWedbush Reaffirms "Neutral" Rating for Vor Biopharma (NYSE:VOR)June 26, 2025 | marketbeat.comVor Bio Announces $175 Million Private PlacementJune 25, 2025 | globenewswire.comVor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune AssetJune 25, 2025 | globenewswire.comEstimating The Fair Value Of Vor Biopharma Inc. (NASDAQ:VOR)June 25, 2025 | finance.yahoo.comVor Biopharma Stock Price History - Investing.comJune 24, 2025 | investing.comVor Biopharma Inc. (VOR) Latest Stock News & Headlines - Yahoo FinanceJune 24, 2025 | finance.yahoo.comVor Bio details extent of Cambridge layoffs in state filingJune 2, 2025 | bizjournals.comVor Biopharma Inc. Advanced Charts - Barron'sMay 29, 2025 | barrons.comStifel cuts Vor Biopharma stock rating amid clinical and financial concernsMay 10, 2025 | investing.comJMP Securities Downgrades Vor Biopharma (VOR)May 9, 2025 | msn.comVor Biopharma draws downgrades on strategic reviewMay 9, 2025 | msn.comJones Trading cuts Vor Biopharma stock rating to HoldMay 9, 2025 | investing.comHC Wainwright & Co. Downgrades Vor Biopharma (VOR)May 9, 2025 | msn.comVor Bio Winding Down Operations, Cutting Workforce, Exploring Potential SaleMay 8, 2025 | marketwatch.comVor Biopharma: Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder ValueMay 8, 2025 | finanznachrichten.deVor Biopharma stock plummets on operation wind-downMay 8, 2025 | in.investing.comVor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder ValueMay 8, 2025 | globenewswire.comVor Biopharma Inc. (NYSE:VOR) Shares Bought by RA Capital Management L.P.May 3, 2025 | marketbeat.comLynx1 Capital Management LP Buys New Stake in Vor Biopharma Inc. (NYSE:VOR)April 29, 2025 | marketbeat.comVor Biopharma faces Nasdaq delisting over low stock priceApril 27, 2025 | investing.comVor Biopharma Inc. (NYSE:VOR) Receives Average Recommendation of "Buy" from AnalystsApril 22, 2025 | marketbeat.comVor Biopharma Inc. (NYSE:VOR) Receives Average Rating of "Buy" from AnalystsMarch 27, 2025 | marketbeat.comVor Bio price target lowered to $5 from $12 at StifelMarch 22, 2025 | markets.businessinsider.comVor Bio price target lowered to $13 from $17.50 at H.C. WainwrightMarch 22, 2025 | markets.businessinsider.comOppenheimer Reaffirms Outperform Rating for Vor Biopharma (NYSE:VOR)March 22, 2025 | marketbeat.comHC Wainwright Lowers Vor Biopharma (NYSE:VOR) Price Target to $13.00March 22, 2025 | marketbeat.comStifel Nicolaus Has Lowered Expectations for Vor Biopharma (NYSE:VOR) Stock PriceMarch 22, 2025 | marketbeat.comWedbush Reaffirms "Outperform" Rating for Vor Biopharma (NYSE:VOR)March 21, 2025 | marketbeat.comVor Biopharma: Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company UpdateMarch 21, 2025 | finanznachrichten.deVor Bio files $350M mixed securities shelfMarch 21, 2025 | markets.businessinsider.comVor Biopharma's (VOR) "Outperform" Rating Reaffirmed at WedbushMarch 21, 2025 | marketbeat.comVor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company UpdateMarch 20, 2025 | globenewswire.com Get Vor Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter. Email Address VOR Media Mentions By Week VOR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VOR News Sentiment▼0.240.57▲Average Medical News Sentiment VOR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VOR Articles This Week▼102▲VOR Articles Average Week Get Vor Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IMNM News Today SNDX News Today CMRX News Today CDMO News Today AVXL News Today SION News Today QURE News Today AVBP News Today CRON News Today XERS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:VOR) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredNobel Prize Material Finally Goes CommercialA Nobel Prize–winning material just got its biggest breakthrough in 30 years. A little-known company has cr...True Market Insiders | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vor Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vor Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
